ASAtsushi Sasaki

Atsushi Sasaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Atsushi Sasaki has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Short- and Long-Term Outcomes after Hepatic Resection for Hepatocellular Carcinoma with Concomitant Esophageal Varices in Patients with Cirrhosis

    by Yuichiro Kawano, Atsushi Sasaki, Seiichiro Kai, Yuichi Endo, Kentaro Iwaki, Hiroki Uchida, Kohei Shibata, Masayuki Ohta, Seigo Kitano

    Hepatic resection for hepatocellular carcinoma (HCC) in cirrhotic patients with esophageal varices (EV) is often avoided because of poor liver function reserve. Outcomes of resection in such cases have not been fully investigated. We conducted a retrospective study of 134 cirrhotic patients (Child–Pugh class A or B) who underwent hepatic resection for HCC, comparing short- and long-term outcomes in patients with EV (n = 31) to those in patients without EV (n = 103). Patients with EV had higher tumor differentiation, fewer instances of portal invasion, lower liver function reserve, and more limited resections than did patients without EV. Of 31 patients with EV, four died of postoperative complication, and nine of liver failure, seven of HCC, two of ruptured EV, and two of other causes. Median survival time for patients who died of liver failure was 59 months. Mortality and morbidity rates after hepatic resection did not differ between patients with and without EV. The 5-year overall survival rate was significantly higher in patients with EV (70.1%) than in those without EV (47.5%, P = 0.045) but did not differ between patients without portal invasion with and without EV (P = 0.55). Presence of EV was not an independent predictor for survival. Short- and long-term outcomes of hepatic resection in HCC patients with and without EV are similar. Limited hepatic resection for early-stage tumor is an option for Child–Pugh class A or B patients with EV.


  • Hepatitis B Virus Infection Predicts Extrahepatic Metastasis After Hepatic Resection in Patients With Large Hepatocellular Carcinoma

    by Atsushi Sasaki, Seiichiro Kai, Yuichi Endo, Kentaro Iwaki, Hiroki Uchida, Kohei Shibata, Masayuki Ohta, Seigo Kitano

    Although extrahepatic metastasis occurs rarely after hepatic resection for hepatocellular carcinoma (HCC), the prognosis of these patients is extremely poor. Predictors of extrahepatic metastasis have not been fully investigated. To identify predictors of extrahepatic metastasis after resection, we retrospectively investigated 77 patients with HCC tumors >50 mm in diameter who underwent hepatic resection. We investigated correlations between postoperative extrahepatic metastasis and clinicopathologic factors as well as extrahepatic metastasis-free survival rate by log rank test and predictors of extrahepatic metastasis by univariate and multivariate logistic regression models. Hepatitis B surface antigen (HBs-Ag) was found in 25 (32.5%) of 77 patients, and extrahepatic metastasis occurred in 26 (33.8%). Patients with extrahepatic metastasis showed better liver function and a high occurrence of HBs-Ag positivity than those without. The 5-year extrahepatic metastasis-free survival rate was worse in patients with HBs-Ag positivity, larger tumors (≥70 mm), higher alfa-fetoprotein level (≥300 ng/mL), and lower indocyanine green retention rate at 15 minutes (ICGR15) (15 (3) were predictors of extrahepatic metastasis (P < .1). By multivariate analysis, HBs-Ag positivity was an independent predictor of postoperative extrahepatic metastasis (P = .04). In patients positive for HBs-Ag, radiologic examination of extrahepatic organs should be performed as a part of the postoperative surveillance. Hepatitis B virus infection may promote establishment of extrahepatic metastasis.


  • Prognostic Value of Preoperative Peripheral Blood Monocyte Count in Patients with Colorectal Liver Metastasis after Liver Resection

    by Atsushi Sasaki, Seiichiro Kai, Yuichi Endo, Kentaro Iwaki, Hiroki Uchida, Masayuki Tominaga, Ryoki Okunaga, Kohei Shibata, Masayuki Ohta, Seigo Kitano


    • 13 December 2005
      • Vol. 52  (66) , 1814-9

    Value of serum carbohydrate antigen 19-9 for predicting extrahepatic metastasis in patients with liver metastasis from colorectal carcinoma.

    by Atsushi Sasaki, Katsunori Kawano, Masafumi Inomata, Kohei Shibata, Toshifumi Matsumoto, Seigo Kitano

    Serum levels of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are frequently elevated in patients with colorectal carcinoma. However, the predictive utility of these two markers has not been fully investigated in patients with liver metastasis. We retrospectively analyzed data obtained from 90 hepatectomy or non-hepatectomy patients with liver metastases from colorectal carcinoma. We examined correlation between serum levels of CEA and CA19-9 and other clinicopathologic factors and performed univariate and multivariate analyses to determine the impact of these tumor markers on extrahepatic metastasis after admission to our hospital. CEA elevation correlated to advanced age (> or = 60 years), and CA19-9 elevation correlated with the site (colon) of primary tumor. Univariate analysis showed that treatment without hepatectomy, > or = 4 hepatic tumors, and CA19-9 elevation had been an adverse effect on extrahepatic disease-free survival time after admission. Multivariate analysis showed that CA19-9 elevation (risk ratio, 1.84) and treatment without hepatectomy (risk ratio, 1.62) had a significant effect on extrahepatic disease-free time. In patients with colorectal liver metastasis, elevation of serum CA19-9 is a risk factor for extrahepatic metastasis, and CEA appears to be useless for predicting extrahepatic metastasis in these patients.


    • 13 December 2005
      • Vol. 52  (66) , 1840-4

    Risk factors for early extrahepatic metastasis in patients with liver metastasis from colorectal carcinoma.

    by Atsushi Sasaki, Yukio Iwashita, Kohei Shibata, Toshifumi Matsumoto, Masayuki Ohta, Masafumi Inomata, Seigo Kitano

    Hepatic resection is one of the most effective therapies for colorectal liver metastasis. However, extrahepatic metastasis is frequently encountered within a short time postoperatively. We attempted to clarify the risk factors for extrahepatic metastasis in patients with colorectal liver metastasis. We retrospectively analyzed data obtained from 116 consecutive patients with colorectal liver metastasis. To determine predictors of extrahepatic metastasis within 1 year of admission for treatment of colorectal liver, we examined 12 clinicopathologic factors by univariate and multivariate logistic regression analyses. Eighty-five underwent hepatectomy and/or thermal ablation (hepatectomy group) and 31 underwent only chemotherapy (non-hepatectomy group). Thirty-one in the hepatectomy group and 19 in the non-hepatectomy group developed extrahepatic metastasis at 1 year after admission. Univariate analysis showed that treatment without hepatectomy and lymphatic vessel permeation at the primary site were significant predictive factors for extrahepatic metastasis within 1 year. Multivariate analysis showed lymphatic permeation of the primary tumor, and treatment without hepatectomy to be significantly related to the occurrence of extrahepatic metastasis within 1 year. The two factors that we identified put patients with colorectal liver metastasis at high risk for extrahepatic metastasis. Systemic chemotherapy may be needed to prevent extrahepatic disease in such patients.


  • Laparoscopic Cholecystectomy for a Double Gallbladder of the Duodenal Type

    by Atsushi Sasaki, Takanori Yoshida, Kenji Kakisako, Masayuki Ohta, Katsuhiro Shimoda, Seigo Kitano

    Double gallbladder is a rare congenital malformation and generally considered a duplication of 1 primordium. We encountered an extremely rare case of double gallbladder of the duodenal type that was considered a duplication of 2 primordia. We were able to diagnose the anomaly preoperatively by endoscopic retrograde cholangiopancreatography and spiral computed tomography after intravenous infusion cholangiography, and laparoscopic removal was successfully performed. To our knowledge, this is the first reported case of double gallbladder of the duodenal type that was diagnosed preoperatively and treated successfully by laparoscopic removal.


  • Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma

    by Atsushi Sasaki, Seiichiro Kai, Yukio Iwashita, Seitaro Hirano, Masayuki Ohta, Seigo Kitano

    BACKGROUND: Intrahepatic disease recurrence is observed frequently after locoregional therapies for patients with hepatocellular carcinoma (HCC). However, the indication for locoregional therapy is still unclear. To clarify the indication for locoregional therapy for small HCC tumors, the authors measured the distance of microsatellites from the main tumor and analyzed the relation between this distance and clinicopathologic factors.METHODS: The authors retrospectively analyzed 100 patients with small HCC tumors (≤ 5 cm in dimension) treated by curative hepatectomy. A microsatellite was defined as invasion into the portal vein or intrahepatic metastasis, and the distance from the main tumor to the most distant microsatellite was determined under light microscopy. The current study investigated the relation between microsatellite distance (0 mm if none present, ≤ 5 mm, and > 5 mm) and clinicopathologic factors, as well as overall and disease‐free survival rates after hepatectomy.RESULTS: Of the 100 patients, 46 had microsatellites with a mean distance of 9.9 mm (median, 5.0 mm). Of the clinicopathologic factors investigated, tumor grade and preoperative α‐fetoprotein level significantly correlated with the presence of a microsatellite. Tumor size and distance to the microsatellite were significantly correlated. All but 1 tumor associated with a microsatellite distance > 5 mm was a high‐grade tumor > 25 mm in greatest dimension. The overall survival rate of patients with a microsatellite distance of > 5 mm was lower than that of patients with a microsatellite distance < 5 mm.CONCLUSIONS: Locoregional therapy, including limited resection and ablation therapies, was appropriate for patients with low‐grade HCC tumors or with tumors < 25 mm in diameter. Cancer 2005. © 2004 American Cancer Society.